subject area of
- BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase Journal Articles
- Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era Journal Articles
- Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy Journal Articles
- Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance Journal Articles
- Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma Journal Articles
- Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib Journal Articles
- Exon-skipping in BCR/ABL is induced by ABL exon 2 Journal Articles
- Expression of p210 and p190 BCR‐ABL due to alternative splicing in chronic myelogenous leukaemia Journal Articles
-
Final report of
TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD ) study Journal Articles -
Gender and
BCR ‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia Journal Articles - Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Journal Articles
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results Journal Articles
- Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All? Journal Articles
- Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013 Conferences